HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity

[1]  N. Zhou,et al.  Characterization of glucose metabolism in breast cancer to guide clinical therapy , 2022, Frontiers in Surgery.

[2]  J. Clohessy,et al.  PI3K drives the de novo synthesis of coenzyme A from vitamin B5 , 2022, Nature.

[3]  Zohreh Hoseinkhani,et al.  Cell line-directed breast cancer research based on glucose metabolism status. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  A. Otto.  Metabolic Constants and Plasticity of Cancer Cells in a Limiting Glucose and Glutamine Microenvironment—A Pyruvate Perspective , 2020, Frontiers in Oncology.

[5]  Takeshi Yamaguchi,et al.  Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy , 2020, Scientific Reports.

[6]  T. Shien,et al.  Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy. , 2020, Japanese journal of clinical oncology.

[7]  Chuanying Xu,et al.  A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo , 2020, Scientific Reports.

[8]  S. McGee,et al.  A systematic flux analysis approach to identify metabolic vulnerabilities in human breast cancer cell lines , 2019, Cancer & Metabolism.

[9]  G. Hoxhaj,et al.  The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism , 2019, Nature Reviews Cancer.

[10]  Zhihui Zhu,et al.  Ceramide regulates interaction of Hsd17b4 with Pex5 and function of peroxisomes. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[11]  Lauren L. Ritterhouse,et al.  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Qiao Wu,et al.  Nuclear Receptor Nur77 Facilitates Melanoma Cell Survival under Metabolic Stress by Protecting Fatty Acid Oxidation. , 2018, Molecular cell.

[13]  F. Filipp,et al.  Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities , 2017, Cancer & metabolism.

[14]  D. Chitale,et al.  Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells , 2017, Scientific Reports.

[15]  H. Kuerer,et al.  Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials , 2017, Annals of Surgical Oncology.

[16]  Takeshi Yamaguchi,et al.  Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation , 2017, Oncotarget.

[17]  A. Schneeweiss,et al.  Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Kristine R Broglio,et al.  Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. , 2016, JAMA oncology.

[19]  L. Thompson,et al.  α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways , 2015, Lipids in Health and Disease.

[20]  A. Kihara,et al.  Metabolism of Very Long-Chain Fatty Acids: Genes and Pathophysiology , 2014, Biomolecules & therapeutics.

[21]  Pier Paolo Pandolfi,et al.  Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.

[22]  A. Kihara.  Very long-chain fatty acids: elongation, physiology and related disorders. , 2012, Journal of biochemistry.

[23]  Tyler J Moss,et al.  The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells , 2012, Molecular systems biology.

[24]  Valerie Speirs,et al.  Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.

[25]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[26]  N. Spector,et al.  Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells , 2005, Oncogene.

[27]  R. Deberardinis,et al.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.

[28]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[29]  P. Hammerman,et al.  Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival , 2003, Molecular and Cellular Biology.

[30]  C. J. Lewis,et al.  Identification and expression of mammalian long-chain PUFA elongation enzymes , 2002, Lipids.

[31]  H. Sprecher,et al.  Elongation of long-chain fatty acids. , 2004, Progress in lipid research.